Regentis Biomaterials (NYSE: RGNT) seeks to sell 3.33M shares; $3.00 assumed

Regentis Biomaterials (NYSE American: RGNT) priced a $6.5 million private placement with accredited and institutional investors at $3.50 per ordinary share, plus accompanying warrants (or $3.4999 per pre-funded warrant). The company will issue 1,857,143 shares (or pre-funded warrants) and warrants to buy 1,857,143 shares. Pre-funded warrants are exercisable at $0.0001; ordinary warrants at $4.20 for five years. Net proceeds will fund its GelrinC pivotal trial, FDA pre-market approval preparation

Regentis Biomaterials (NYSE: RGNT) shares moved sharply after the company filed a Form 6-K with the SEC, saying it requested withdrawal of its Form F-1 registration statement and decided not to pursue the related public offering. The stock rose 506.45% to $9.40 intraday, then fell 9.15% to $8.54 in after-hours.

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.